Literature DB >> 18950884

Decline of dose coverage between intraoperative planning and post implant dosimetry for I-125 permanent prostate brachytherapy: comparison between loose and stranded seed implants.

Marinus A Moerland1, Marijke J H van Deursen, Sjoerd G Elias, Marco van Vulpen, Ina M Jürgenliemk-Schulz, Jan J Battermann.   

Abstract

BACKGROUND AND
PURPOSE: In permanent prostate brachytherapy the dose distributions 4 weeks post implant differ from the intraoperative dose distributions. The purpose of this study is to compare intraoperative planning and post implant dosimetry for loose and stranded seed implants.
MATERIALS AND METHODS: This study investigates prostate dose coverage in 389 patients with stage T1 or T2 prostate cancer treated in the years 2005, 2006 and 2007. The patients received either a loose seed or a stranded seed implant. All patients had US-based intraoperative planning and CT/MRI-based post implant dosimetry after 4 weeks.
RESULTS: Intraoperative and post implant D(90) values amounted 183+/-13 Gy (mean+/-standard deviation) and 161+/-30 Gy, respectively. Decline of D(90) values (mean and 95% confidence interval) between intraoperative planning and post implant dosimetry for RAPID strand (n=67), Intersource strand (n=136) and loose selectSeeds (n=186) implants amounted to -40 (-45 to -34) Gy, -25 (-28 to -21) Gy and -15 (-18 to -21) Gy, respectively.
CONCLUSIONS: The patients treated in the period 2005-2007 with stranded or loose seed implants had on average adequate D(90) values of 161+/-30 Gy. Post implant D(90) values were 22+/-27 Gy lower compared to intraoperative planning. Decline of dose coverage between intraoperative planning and post implant dosimetry was significantly larger for the stranded seed implants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18950884     DOI: 10.1016/j.radonc.2008.09.013

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer.

Authors:  E Le Fur; J P Malhaire; D Baverez; F Delage; M A Perrouin-Verbe; F Schlurmann; S Guerif; G Fournier; O Pradier; A Valeri
Journal:  Strahlenther Onkol       Date:  2012-11-11       Impact factor: 3.621

2.  Benefits of a dual sagittal crystal transducer for ultrasound imaging during I-125 seed implantation for permanent prostate brachytherapy.

Authors:  Emmie Kaljouw; Bradley Pieters; Kees Koedooder; Cees Lucas; Caro Koning
Journal:  J Contemp Brachytherapy       Date:  2012-09-29

3.  Re-implantation after insufficient primary 125-i permanent prostate brachytherapy.

Authors:  Paul Martin Putora; Ludwig Plasswilm; Wolf Seelentag; Johann Schiefer; Patrick Markart; Hans-Peter Schmid; Daniel Engeler
Journal:  Radiat Oncol       Date:  2013-08-06       Impact factor: 3.481

4.  Comparison of implant quality between intraoperatively built custom-linked seeds and loose seeds in permanent prostate brachytherapy using sector analysis.

Authors:  Norihisa Katayama; Mitsuhiro Takemoto; Atsushi Takamoto; Hiroki Ihara; Kuniaki Katsui; Shin Ebara; Yasutomo Nasu; Susumu Kanazawa
Journal:  J Radiat Res       Date:  2016-03-13       Impact factor: 2.724

5.  Dosimetry advantages of intraoperatively built custom-linked seeds compared with loose seeds in permanent prostate brachytherapy.

Authors:  Masahiro Inada; Masaki Yokokawa; Takafumi Minami; Kiyoshi Nakamatsu; Yasumasa Nishimura
Journal:  J Contemp Brachytherapy       Date:  2017-10-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.